万维提示：
1、该刊只有国际刊号。
2、投稿方式：在线投稿。
3、官网网址：
https://mednexus.org/journal/jco
4、投稿系统：
https://www.editorialmanager.com/jcardiooncol/default2.aspx
5、中华医学期刊全文数据库：
https://www.yiigle.com/Journal/JCO
6、官网电话：0411-83635963-2139
7、官网邮箱：joco@cmaph.org
8、出刊日期：季刊，一年出版四期。
2026年1月12日星期一
Instructions for Authors
【官网信息】
The Editorial Office is pleased to answer any questions you may have about preparing your manuscript in accordance with our guidelines.
Email: joco@cmaph.org
AIMS AND SCOPE
Journal Aims:
Promote Multidisciplinary Collaboration: To highlight and advance the role of multidisciplinary teams (MDTs) in the diagnosis, treatment, and management of cardio-oncology patients, fostering a holistic and patient-centered approach to care.
Disseminate Cutting-Edge Research: To publish high-quality, innovative research that spans the entire spectrum of cardio-oncology, from basic and translational science to clinical studies and outcomes research.
Educate Healthcare Professionals: To provide comprehensive knowledge that support the continuous professional development of all members of the MDT, including cardiologists, oncologists, radiologists, surgeons, nurses, and allied health professionals.
Address Global Health Disparities: To promote research and practices that address health disparities in cardio-oncology care, ensuring equitable access to the latest advancements in diagnosis, treatment, and prevention worldwide.
Promote Patient-Centered Care: To emphasize the importance of involving patients and their families in treatment decisions and care planning, incorporating patient perspectives and experiences into the journal’s content.
Disseminate knowledge through a diverse range of content formats, including original research articles, reviews, commentaries, patient case studies, interactive multimedia content, sharing best practices tailored to different healthcare professionals within the Cardio-Oncology MDT.
Journal Scope:
The Journal of Cardio-Oncology welcomes submissions that cover a broad range of topics within the field, including but not limited to:
Clinical Research: Studies on the diagnosis, treatment, and management of cardiovascular complications in cancer patients, including clinical trials, case reports, and observational studies.
Basic and Translational Science: Research on the underlying mechanisms of cardiotoxicity, biomarkers, and susceptibility to cardiovascular injury caused by cancer therapies.
Multidisciplinary Team Approaches: Articles that showcase the benefits and challenges of MDTs in cardio-oncology, including best practices, protocols, and case studies, including clinical practice guidelines and clinical consensus statements.
Innovative Therapies and Technologies: Research on new therapeutic strategies, emerging technologies, and interventions that improve the care of cardio-oncology patients (such as AI and precision medicine).
Patient and Family Perspectives: Narratives and studies that highlight the experiences and outcomes of patients and their families, emphasizing the importance of patient-centered care (including psychosocial aspects of cancer and cardiovascular disease, including patient advocacy and support strategies).
Health Policy and Advocacy: Discussions on healthcare policies, organizational strategies, and advocacy efforts that support the integration and effectiveness of MDTs in cardio-oncology.
Global Health: Research addressing the global disparities in cardio-oncology care, with a focus on innovative solutions for low- and middle-income countries.
Educational Resources: Educational articles, reviews, and multimedia content aimed at the continuous education and training of MDT members in the latest advancements and best practices in cardio-oncology.
ONLINE SUBMISSION
First-time Users
Please click the Register button at https://www.editorialmanager.com/jcardiooncol/default.aspx. Upon successful registration, you will be sent an email providing your username and password. Save this information for future reference.
Note: If you have received an email from us with an assigned username and password, or if you are a repeat user, do not register again. Once you have an assigned username and password, you do not have to re-register.
Authors
Please click the Login button from the menu at the top of the page and login to the system as an author. Submit your manuscript according to the author instructions. You will be able to track the process of your manuscript through the system.
JOURNAL POLICIES
Duplicate Publication
Manuscripts are reviewed for possible publication with the understanding that they are being submitted only to the Journal of Cardio-Oncology and have not been published, simultaneously submitted, or already accepted for publication elsewhere. The Editorial team may subject any manuscript submitted for consideration of publication in the Journal of Cardio-Oncology to plagiarism-detection software.
This does not preclude consideration of a manuscript that has been rejected by another journal or a complete report that follows publication of preliminary findings elsewhere, usually in the form of an abstract. Copies of any possibly duplicate published material should be submitted with the manuscript under consideration, with a statement in the cover letter as to why the manuscript currently being submitted is not a duplicate publication.
Disclosure of Conflicts
Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared. All sources of funding should be acknowledged in the manuscript.
All relevant conflicts of interest and sources of funding should be included on the title page of the manuscript with the heading "Conflicts of Interest” and “Source of Funding".
For example: “Conflicts of Interest: A has received honoraria from Company Z. B is currently receiving a grant (#12345) from Organization Y, and is on the speaker's bureau for Organization X - the CME organizers for Company A. For the remaining authors none were declared.”
“Source of Funding”: list all the grant supports/funders for the study.
A financial disclosure section is part of the submission process and must be completed by each author at first revision. This information is for review by the Editors but will be published if relevant to the content of the accepted manuscript.
The primary purpose of the disclosure section is to determine whether authors have received any commercial financial support that could create a conflict of interest. In addition to monetary interests, a potential for conflict of interest can exist whether or not an individual believes that a relationship (such as dual commitments, competing interests, or competing loyalties) affects his or her scientific judgment. Please review ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals at the following link:
http://www.icmje.org/conflicts-of-interest.
Studies in Humans and Animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.
Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
Authors describing studies involving animals must have consulted the ‘Animal Research: Reporting In Vivo Experiments’ (ARRIVE) 2.0 guidelines, developed by the NC3Rs to improve standards of reporting, ensuring that the data from animal experiments can be fully scrutinized and utilized. Articles reporting in vivo experiments must adhere to the ARRIVE Essential 10 checklist as a minimum, and we encourage authors to use the full ARRIVE 2.0 checklist. The relevant information outlined in these guidelines should be included in the appropriate section of the article.
Ethics
When reporting studies on human subjects, author should indicate whether the procedures followed were in accordance with the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). For prospective studies involving human participants, authors are expected to mention about approval of regional/national/institutional or independent ethics committee or review board, obtaining informed consent from adult research participants and obtaining assent for children aged over 7 years participating in the trial. The age beyond which assent would be required could vary as per regional and/or national guidelines. Ensure confidentiality of subjects by desisting from mentioning participants’ names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the institution’s or a national research council’s guide for, or any national law on the care and use of laboratory animals was followed.
Evidence for approval by a local ethics committee (for both human as well as animal studies) must be supplied by the authors on demand. Animal experimental procedures should be as humane as possible, and the details of anesthetics and analgesics used should be clearly stated. The ethical standards of experiments must be in accordance with the guidelines provided by the ARRIVE and World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving experimental animals and human beings, respectively. The journal will not consider any paper which is ethically unacceptable. A statement on ethics committee permission and ethical practices must be included in all research articles under the “Methods” section.
We reserve the right to decline publication of a paper even after it has been accepted if it becomes apparent that there are serious problems with the scientific content or violations of our publishing policies.
Protection of Patients’ Rights to Privacy
Identifying information should not be published in written descriptions, photographs, sonograms, CT scans, etc., and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian, wherever applicable) gives written informed consent for publication. Authors should remove patients’ names from figures unless they have obtained written informed consent from the patients. The journal abides by ICMJE guidelines: (1) Authors, not the journals nor the publisher, need to have the patient consent form before the publication related to patient privacy and have the form properly archived by the author. (2) If the publication includes some facial images that make the patients identifiable, a statement about the patient’s consent needs to be present in the manuscript.
......
更多详见：
https://mednexus.org/journal/jco/authors/instructions
